An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
Treating CLL with CALQUENCE® (acalabrutinib)
December 31st 2020, 4:00pm
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
December 14th 2020, 4:00pm
More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.
December 14th 2020, 2:00pm
Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.
December 9th 2020, 2:00pm
The combination of ublituximab and umbralisib, two novel compounds, was able to safely prolong progression-free survival with low rates of toxicities in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy regardless of prior treatment.
December 8th 2020, 10:00pm
At a median follow-up of 25.9 months, 17% of the patient population who received Calquence monotherapy experienced a cardiac toxicity of any severity, which led to treatment discontinuation in only seven patients.
December 8th 2020, 7:00pm
The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.
December 7th 2020, 8:00pm
Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.
December 7th 2020, 2:00pm
In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
December 5th 2020, 9:33pm
Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.
December 5th 2020, 9:07pm
Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.
How TikTok Helped One Survivor Discover Connection and Community
Certain Dietary Patterns May Be Associated with Lower Risk of Colorectal Cancer
Managing the Stress of Medical Leave and Insurance Forms
‘I’m Not Always Happy, But I’m Happy Right Now’ with Endometrial Cancer
